Clinical effect of high-dose or low-dose of atorvastatin on no-flowphenomenon after percutaneous coronary int ervention in patients with acute ST-elevation myocardial infarction
Wu Qaing
Wang Chulin
Lin Yupeng
Chen Xiaoying
Abstract：Obj cetive To investigate the clinical effect of high d-ose or low-dose of atorvastatin on no-flow phenomenon after percutaneous coronary intervention ( PCI)in patients with acute ST-elevation myocardial infarc-tion. Methods Totally 64 patients who were diagnosed of ST-elevation myocardial infarction and received PCI from October 2011 to March 2013 in Peoples′Hospital of Jieyang city were randomly divided into high-dose atorv-astatin group ( atorvastatin 80 mg, n=32 ) and low-dose atorvastatin group ( atorvastatin 20 mg, n=32 ) .The thrombolysis in myocardial infarction ( TIMI) myocardial perfusion grade , electrocardiogram and major adverse car-diovascular event(MACE) were compared between the two groups.Results The rate of (MACE) was 6.2%(2/32) in high-dose atorvastatin group, compared with 37.5%(12/32) in low-dose atorvastatin group (χ2 =9.143, P<0.05).Ratio of TIMI 0, TIMI 1 in patients with low-dose atorvastatin group was 28.1%(7/32) and 37.5%(12/32), respectively.Ratio of TIMI 0, TIMI 1 in patients with low-dose atorvastatin group was 6.3%(2/32) and 3.1%(1/32), respectively;the high-dose atorvastatin group was significantly lower than the low -dose atorvastatin group(χ2=5.379,11.680, P<0.05).TIMI 2, TIMI 3 rate in low-dose atorvastatin group was 21.8%(7 /32) and 12.5%(4/32), respectively.TIMI 2, TIMI 3 rate in high-dose atorvastatin group were 46.9%(15/32) and 43.8%(14/32), respectively;the high-dose atorvastatin group were significantly higher than the low-dose atorvastatin group (χ2 =4.433, 7.729, both P<0.05).ST elevation was (0.15 ±0.04)mm in the low-dose atorvastatin group, as was (0.06 ±0.02)mm in the high-dose atorvastatin group;high-dose atorvastatin group was significantly lower than low-dose atorvastatin group (t=3.323 , P<0.05).ST down was (0.22 ± 0.07)mm in the low-dose atorvastatin group, as was (0.07 ±0.02)mm in the high-dose atorvastatin group;high-dose atorvastatin group was significantly lower than low-dose atorvastatin group (t=3.451, P<0.05).Total cho-lesterol was (5.4 ±0.4)mmol/L in the low-dose atorvastatin group, as was(4.4 ±0.3)mmol/L in the high-dose atorvastatin group; high-dose atorvastatin group was significantly lower than low -dose group (t =3.310, P <0.05).TG was (1.98 ±0.16 )mmol/L in the low-dose atorvastatin group, as was (1.38 ±0.21)mmol/L in the high-dose atorvastatin group; high-dose atorvastatin group was significantly lower than low-dose atorvastatin group (t=3.962, P<0.05).LDL-C was (3.38 ±0.41) mmol/L in the low-dose atorvastatin group; it was (2.53 ± 0.15)mmolL/in the high-dose atorvastatin group;high-dose atorvastatin group was significantly lower than low -dose atorvastatin group(t =3.385, P<0.05).HDL-C was (1.16 ±0.11)mmol/L in the low-dose atorvastatin group;it was (1.49 ±0.14)mmol/L in the high-dose atorvastatin group;high-dose atorvastatin group was significantly higher than low-dose atorvastatin group(t=3.293, P<0.05).Conclusion Atorvastatin can improve myocardial perfusion and reduce no-reflow phenomenon after PCI .
Keywords：Acute myocardial infarctionNo-flow phenomenonAtorvastatin
Publication Date：2014-09-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1262-1266 )